The national
Conditions
Interventions
1:Entecavir+Pegylation of IFN
2:Entecavir+Pegylation of IFN+Thymopentin
3:Pegylation of IFN+Thymopentin
Sponsors
Beijing YouAn Hospital, Capital Medial University
Eligibility
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years of age, gender not limited; 2. Comply with 2012 chronic hepatitis B prevention and treatment guidelines: HBsAg positive more than 6 months and: A) HBVDNA more than 2E+5IU/ml; B) the HBeAg positive; C) HBsAg concentration more than 1000 IU/ml (the determination is Roche electrochemical luminescence method and use the quantitative detection); 3. 2 x ULN less than ALT less than 10 x ULN, TBIL less than 2 x ULN. Or ALT less than 2 x ULN, but liver histology shows Knodell HAI more than 4 ,or inflammatory necrosis more than G2, or fibrosis more than S2; 4. To understand and voluntarily sign informed consent; 5. Able to comply with the research programs and visit plan in the scheme.
Exclusion criteria
Exclusion criteria: The patients who do not conform to the Interferon application, or conform to one of the following subjects will not be allowed to be included in the test: 1. The combination of other virus infection (HAV, HCV, HEV, EBV, CMV, HIV, etc.); 2. Other causes of liver disease, including alcoholic liver disease, nonalcoholic fatty hepatitis, drug-induced hepatitis, autoimmune hepatitis, etc.; 3. With liver cancer, serious liver disease and other important viscera dysfunction; 4. Pregnancy and lactation female patients; 5. Have the history of the main organ transplantation; 6. Routine blood neutrophils count less than 1.0*10^9/L; The platelet count less than 50*10^9/L; 7. Have other severe autoimmune diseases; Spirit, nervous system disease; Serious blood system diseases; Severe renal disease; The uncontrollable digestive disease; Endocrine diseases; Severe respiratory disease; Diseases of the cardiovascular system; Retinopathy; Used nucleoside antiviral drugs in half a year; And clinical doctors do not think suitable as participants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA quantitative;Liver function;Abdominal ultrasound;Breast enhancement CT;Five makers of hepatitis B; | — |
Countries
China
Contacts
Public ContactJun Lv
Outcome results
None listed